Abu Dhabi white paper sets four priorities for advanced therapies
A white paper proposes ways to connect genomic science, health data and research with patient care; its projections are forecasts.
- Publish date: 2026-10-21
- Category: Standards & Policy
- Original source: Emirates News Agency (WAM)
- Reading time: 1 min read
Future Health – A Global Initiative from Abu Dhabi and Strategy& issued a white paper on translating medical innovation into patient care. It sets four priorities: precision trials using genomic and longitudinal health data; clearer regulated-access pathways with continued evidence gathering; stronger therapeutic capabilities in areas of Abu Dhabi expertise; and using long-term patient outcomes to guide care and research. Strategy& estimates cell and gene therapies and RNA- and DNA-based treatments could grow 7–8 times from current levels, while small-molecule and antibody therapies may retain the largest market share through 2033. These are forecasts. The paper presents a proposed approach; it does not announce therapies developed, approved or delivered in Abu Dhabi.